RhumbLine Advisers’s POMDOCTOR LIMITED Class A Ordinary Shares POM Stock Holding History

RhumbLine Advisers’s Portfolio POM Stock Details POM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$39	Hold	41	–	–	﹤0.01%	4029
2026 Q2	$60	Sell	41 -1	-2%	-$4	﹤0.01%	4103
2026 Q1	$192	Hold	42	–	–	﹤0.01%	4039
2025 Q4	$221	Buy	+42	New	+$2.74K	﹤0.01%	4082

Other funds holding POM

UBS Group Zurich, Switzerland $765B AUM 28.39% 1-Year Est. Return

Caitong International Asset Management Hong Kong $1.04B AUM 150.26% 1-Year Est. Return

JP Morgan Chase New York $1.84T AUM 33.86% 1-Year Est. Return

RhumbLine Advisers's POM Position: Q3 2026 in Review

RhumbLine Advisers held its POMDOCTOR LIMITED Class A Ordinary Shares (POM) position steady in Q3 2026 at 41 shares worth $39. The position accounts for ﹤0.01% of the portfolio, ranked #4029.

RhumbLine Advisers first reported a position in POM in Q4 2025 and has held it in 4 quarters since. The position peaked at $221 in Q4 2025. 4 funds tracked by Wall St. Rank hold POM as of Q3 2026.

RhumbLine Advisers held 41 shares of POMDOCTOR LIMITED Class A Ordinary Shares worth $39 as of Q3 2026.
RhumbLine Advisers left its POMDOCTOR LIMITED Class A Ordinary Shares share count unchanged in Q3 2026.
POMDOCTOR LIMITED Class A Ordinary Shares made up ﹤0.01% of RhumbLine Advisers's portfolio in Q3 2026, its #4029 holding.
RhumbLine Advisers first reported a position in POMDOCTOR LIMITED Class A Ordinary Shares in Q4 2025 and has held it in 4 quarters since.
RhumbLine Advisers's POMDOCTOR LIMITED Class A Ordinary Shares position peaked at $221 in Q4 2025.
4 funds tracked by Wall St. Rank held POMDOCTOR LIMITED Class A Ordinary Shares as of Q3 2026.

Based on RhumbLine Advisers's 13F filing for Q3 2026, filed 10 Nov 2026.